Survival outcomes (mPFS 8.2 months; 12-month OS 80.8%) compare favorably with typical first-line chemo-immunotherapy ...
Iza-bren and Tagrisso combination showed a 100% objective response rate in EGFR-mutant NSCLC at a 2.5 mg/kg dose. The 12-month progression-free survival and overall survival rates were 92% and 95%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results